• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC CORPORATION ROTABLATOR ROTATIONAL ATHERECTOMY SYSTEM; CATHETER, CORONARY, ATHERECTOMY

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC CORPORATION ROTABLATOR ROTATIONAL ATHERECTOMY SYSTEM; CATHETER, CORONARY, ATHERECTOMY Back to Search Results
Model Number 3240
Device Problem Output Problem (3005)
Patient Problems Chest Pain (1776); Non specific EKG/ECG Changes (1817); ST Segment Elevation (2059)
Event Date 10/15/2020
Event Type  Injury  
Event Description
It was reported that the burr was difficult to remove.A rotalink plus rotablator rotational atherectomy system were selected for use.After the third passage, the burr unexpectedly stopped downstream from the lesion.Several attempts were made to start rotation, however, rotation stopped within 5 seconds.Dynaglide function was not working.It was not possible to remove the burr and the patient experienced st segment elevation coronary syndrome and chest pain.The patient required deep intubation, sedation, injection of arterial vasodilators, and parallel placement of a guide in order to remove the burr from the circumflex artery.No further patient complications were reported.
 
Event Description
It was reported that the burr was difficult to remove.A rotalink plus rotablator rotational atherectomy system were selected for use.After the third passage, the burr unexpectedly stopped downstream from the lesion.Several attempts were made to start rotation, however, rotation stopped within 5 seconds.Dynaglide function was not working.It was not possible to remove the burr and the patient experienced st segment elevation coronary syndrome and chest pain.The patient required deep intubation, sedation, injection of arterial vasodilators, and parallel placement of a guide in order to remove the burr from the circumflex artery.No further patient complications were reported.
 
Manufacturer Narrative
Device evaluated by mfr: the rotablator console rc401724 was received in good condition, but the warranty label was broken.The footpedal and airhose were received in good condition.A functional test showed the footpedal passed the specifications for cis rotablator functional test.A functional test showed the airhose passed the specifications for cis rotablator functional test.Functional testing of the console showed the console failed the specifications for cis rotablator functional test.The rotablator console failed functional testing on the pneumatic test fixture.It also failed functional testing on the pressure gauge on the device.These failures of low pressure can cause intermittent failure to reach optimum speeds during a procedure.The dynaglide mode functioned as it should throughout the functional test.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ROTABLATOR ROTATIONAL ATHERECTOMY SYSTEM
Type of Device
CATHETER, CORONARY, ATHERECTOMY
Manufacturer (Section D)
BOSTON SCIENTIFIC CORPORATION
two scimed place
maple grove MN 55311
MDR Report Key11211076
MDR Text Key228166631
Report Number2134265-2021-00615
Device Sequence Number1
Product Code MCX
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Type of Report Initial,Followup
Report Date 03/22/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Model Number3240
Device Catalogue Number3240
Device Lot NumberRC401724
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer03/03/2021
Initial Date Manufacturer Received 01/13/2021
Initial Date FDA Received01/21/2021
Supplement Dates Manufacturer Received03/16/2021
Supplement Dates FDA Received03/22/2021
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
-
-